These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 24865310)

  • 1. The Alzheimer structural connectome: changes in cortical network topology with increased amyloid plaque burden.
    Prescott JW; Guidon A; Doraiswamy PM; Roy Choudhury K; Liu C; Petrella JR;
    Radiology; 2014 Oct; 273(1):175-84. PubMed ID: 24865310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations Between Amyloid and Tau Pathology, and Connectome Alterations, in Alzheimer's Disease and Mild Cognitive Impairment.
    King-Robson J; Wilson H; Politis M;
    J Alzheimers Dis; 2021; 82(2):541-560. PubMed ID: 34057079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
    Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM
    Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations Between Positron Emission Tomography Amyloid Pathology and Diffusion Tensor Imaging Brain Connectivity in Pre-Clinical Alzheimer's Disease.
    Hwang SJ; Adluru N; Kim WH; Johnson SC; Bendlin BB; Singh V
    Brain Connect; 2019 Mar; 9(2):162-173. PubMed ID: 30255713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer's disease-causing Presenilin-1 E280A mutation carriers.
    Ghisays V; Lopera F; Goradia DD; Protas HD; Malek-Ahmadi MH; Chen Y; Devadas V; Luo J; Lee W; Baena A; Bocanegra Y; Guzmán-Vélez E; Pardilla-Delgado E; Vila-Castelar C; Fox-Fuller JT; Hu N; Clayton D; Thomas RG; Alvarez S; Espinosa A; Acosta-Baena N; Giraldo MM; Rios-Romenets S; Langbaum JB; Chen K; Su Y; Tariot PN; Quiroz YT; Reiman EM;
    Neuroimage Clin; 2021; 31():102749. PubMed ID: 34252876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid Deposition Is Greater in Cerebral Gyri than in Cerebral Sulci with Worsening Clinical Diagnosis Across the Alzheimer's Disease Spectrum.
    Walden LM; Hu S; Madabhushi A; Prescott JW;
    J Alzheimers Dis; 2021; 83(1):423-433. PubMed ID: 34334397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study.
    Wu KY; Liu CY; Chen CS; Chen CH; Hsiao IT; Hsieh CJ; Lee CP; Yen TC; Lin KJ
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1067-76. PubMed ID: 26739329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
    Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
    J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease.
    Edmonds EC; Bangen KJ; Delano-Wood L; Nation DA; Furst AJ; Salmon DP; Bondi MW;
    J Int Neuropsychol Soc; 2016 Nov; 22(10):978-990. PubMed ID: 27903335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Florbetapir Regional Distribution in Cerebral Amyloid Angiopathy and Alzheimer's Disease: A PET Study.
    Planton M; Saint-Aubert L; Raposo N; Payoux P; Salabert AS; Albucher JF; Olivot JM; Péran P; Pariente J
    J Alzheimers Dis; 2020; 73(4):1607-1614. PubMed ID: 31958082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiparametric graph theoretical analysis reveals altered structural and functional network topology in Alzheimer's disease.
    Lin SY; Lin CP; Hsieh TJ; Lin CF; Chen SH; Chao YP; Chen YS; Hsu CC; Kuo LW
    Neuroimage Clin; 2019; 22():101680. PubMed ID: 30710870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.
    Camus V; Payoux P; Barré L; Desgranges B; Voisin T; Tauber C; La Joie R; Tafani M; Hommet C; Chételat G; Mondon K; de La Sayette V; Cottier JP; Beaufils E; Ribeiro MJ; Gissot V; Vierron E; Vercouillie J; Vellas B; Eustache F; Guilloteau D
    Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):621-31. PubMed ID: 22252372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional brain hypometabolism is unrelated to regional amyloid plaque burden.
    Altmann A; Ng B; Landau SM; Jagust WJ; Greicius MD;
    Brain; 2015 Dec; 138(Pt 12):3734-46. PubMed ID: 26419799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease.
    Kobylecki C; Langheinrich T; Hinz R; Vardy ER; Brown G; Martino ME; Haense C; Richardson AM; Gerhard A; Anton-Rodriguez JM; Snowden JS; Neary D; Pontecorvo MJ; Herholz K
    J Nucl Med; 2015 Mar; 56(3):386-91. PubMed ID: 25655625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping the effects of ApoE4, age and cognitive status on 18F-florbetapir PET measured regional cortical patterns of beta-amyloid density and growth.
    Murphy KR; Landau SM; Choudhury KR; Hostage CA; Shpanskaya KS; Sair HI; Petrella JR; Wong TZ; Doraiswamy PM;
    Neuroimage; 2013 Sep; 78():474-80. PubMed ID: 23624169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural brain network correlations with amyloid burden in elderly individuals at risk of Alzheimer's disease.
    Ota M; Numata Y; Kitabatake A; Tsukada E; Kaneta T; Asada T; Meno K; Uchida K; Suzuki H; Korenaga T; Arai T
    Psychiatry Res Neuroimaging; 2022 Jan; 319():111415. PubMed ID: 34839208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18(AV-45) positron emission tomography.
    Rosenberg PB; Wong DF; Edell SL; Ross JS; Joshi AD; Brašić JR; Zhou Y; Raymont V; Kumar A; Ravert HT; Dannals RF; Pontecorvo MJ; Skovronsky DM; Lyketsos CG
    Am J Geriatr Psychiatry; 2013 Mar; 21(3):272-8. PubMed ID: 23395194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid burden in the hippocampus and default mode network: relationships with gray matter volume and cognitive performance in mild stage Alzheimer disease.
    Chang YT; Huang CW; Chang YH; Chen NC; Lin KJ; Yan TC; Chang WN; Chen SF; Lui CC; Lin PH; Chang CC
    Medicine (Baltimore); 2015 Apr; 94(16):e763. PubMed ID: 25906109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes.
    Schreiber S; Landau SM; Fero A; Schreiber F; Jagust WJ;
    JAMA Neurol; 2015 Oct; 72(10):1183-90. PubMed ID: 26280102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.